토글닫기
팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website. Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

HR Management/Regulations Maintenance

Business Management

Purchase/General affairs

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Planning

Develop plans to materialize strategy and analyze business proposals

Assess the company’s operational and strategic performance

Provide support and insight into significant organizational changes

Business Development

Collaborate with global partners on potential out-licensing deals

Establish global marketing strategies (marketability, feasibility)

Establish new business and collaboration plans

Communication

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

  • Home
  • PR

PR

News

News

게시물 상세
OliX Pharmaceuticals Announces Completion of $37.2 Million Capital Raise
Date : 2020-12-04     View : 429

OliX Pharmaceuticals Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally

 

- Capital to fund construction of RNA synthesis GMP facility in San Diego 

- Supports company’s goal of having 10 programs entered into clinical trials by 2024


Learn more: https://apnews.com/press-release/globe-newswire/technology-business-health-pharmaceutical-manufacturing-health-care-industry-e9241a601ec0a5f8c3b546e882b78fe3 


Source _ OliX Pharmaceuticals
Prev OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics
Next OliX Announces FDA Clearance of the Phase 2a Clinical Trial IND for Hypertrophic Scars
List